CN102781454B - 用于治疗性治疗肿瘤疾病的来源于成体干细胞的微泡（mv） - Google Patents

用于治疗性治疗肿瘤疾病的来源于成体干细胞的微泡（mv） Download PDF

Info

Publication number
CN102781454B
CN102781454B CN201180011925.0A CN201180011925A CN102781454B CN 102781454 B CN102781454 B CN 102781454B CN 201180011925 A CN201180011925 A CN 201180011925A CN 102781454 B CN102781454 B CN 102781454B
Authority
CN
China
Prior art keywords
cells
mvs
microvesicles
tumors
stem cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180011925.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN102781454A (zh
Inventor
斯特凡尼亚·布鲁诺
玛利亚·比阿特丽斯·赫雷拉桑切斯
瓦伦丁娜·丰萨托
乔瓦尼·卡穆西
奇罗·泰塔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fresenius Medical Care Deutschland GmbH
Original Assignee
Fresenius Medical Care Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fresenius Medical Care Deutschland GmbH filed Critical Fresenius Medical Care Deutschland GmbH
Publication of CN102781454A publication Critical patent/CN102781454A/zh
Application granted granted Critical
Publication of CN102781454B publication Critical patent/CN102781454B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201180011925.0A 2010-03-02 2011-02-28 用于治疗性治疗肿瘤疾病的来源于成体干细胞的微泡（mv） Active CN102781454B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10425052A EP2363136A1 (en) 2010-03-02 2010-03-02 Microvesicles (MVs) derived from adult stem cells for use in the therapeutic treatment of a tumor disease
EP10425052.7 2010-03-02
PCT/EP2011/052945 WO2011107437A1 (en) 2010-03-02 2011-02-28 Microvesicles (mvs) derived from adult stem cells for use in the therapeutic treatment of a tumor disease

Publications (2)

Publication Number Publication Date
CN102781454A CN102781454A (zh) 2012-11-14
CN102781454B true CN102781454B (zh) 2015-12-16

Family

ID=42306621

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180011925.0A Active CN102781454B (zh) 2010-03-02 2011-02-28 用于治疗性治疗肿瘤疾病的来源于成体干细胞的微泡（mv）

Country Status (10)

Country Link
US (4) US9717760B2 (enExample)
EP (2) EP2363136A1 (enExample)
JP (1) JP5841952B2 (enExample)
CN (1) CN102781454B (enExample)
DK (1) DK2542250T3 (enExample)
ES (1) ES2554492T3 (enExample)
HU (1) HUE026292T2 (enExample)
PL (1) PL2542250T3 (enExample)
PT (1) PT2542250E (enExample)
WO (1) WO2011107437A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2363136A1 (en) * 2010-03-02 2011-09-07 Fresenius Medical Care Deutschland GmbH Microvesicles (MVs) derived from adult stem cells for use in the therapeutic treatment of a tumor disease
TWI629990B (zh) 2010-05-12 2018-07-21 英瑞金公司 生物活性腎細胞
ITRM20110403A1 (it) * 2011-07-28 2013-01-29 Ospedale Pediatrico Bambino Gesu Microvescicole isolate da cellule mesenchimali come agenti immunosoppressori.
CN102357071B (zh) * 2011-10-26 2013-10-23 重庆医科大学附属儿童医院 载紫杉醇纳米微泡及其制备方法
HRP20181515T1 (hr) * 2011-11-30 2018-11-16 Astellas Institute For Regenerative Medicine Mezenhimne stromalne stanice i upotreba povezana s njima
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
US11286463B2 (en) 2012-03-08 2022-03-29 Advanced ReGen Medical Technologies, LLC Reprogramming of aged adult stem cells
WO2014011407A2 (en) 2012-07-12 2014-01-16 Imstem Biotechnology, Inc. Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
JP6353073B2 (ja) 2013-12-20 2018-07-04 アドヴァンスド リジェン メディカル テクノロジーズ，エルエルシー 細胞回復のための組成物並びにその作製及び使用方法
US10772911B2 (en) 2013-12-20 2020-09-15 Advanced ReGen Medical Technologies, LLC Cell free compositions for cellular restoration and methods of making and using same
CR20160495A (es) * 2014-03-24 2017-05-29 Advanced Regen Medical Tech Llc Composiciones libres de células para la restauración de células y métodos para la preparación y utilización de las mismas
US10538738B2 (en) * 2014-05-19 2020-01-21 Eleftherios Papoutsakis Megakaryocytic particles and microparticles for cell therapy and fate modification of stem and progenitor cells
BR112018072198A2 (pt) 2016-04-29 2019-02-12 Advanced ReGen Medical Technologies, LLC composição compreendendo micrornas, método de preparação de uma composição de célula-tronco restaurada, formulação farmacêutica e kit
CN111601890B (zh) * 2017-12-14 2024-04-19 联合细胞Ev股份公司 用于治疗肾癌的包含miRNA的药物载体
US10717981B2 (en) 2018-01-18 2020-07-21 Advanced ReGen Medical Technologies, LLC Therapeutic compositions and methods of making and using the same
WO2019197442A1 (en) * 2018-04-12 2019-10-17 Unicyte Ev Ag A combination of active ingredients for the treatment of tumor
CN111494417B (zh) * 2020-02-10 2024-04-09 寇晓星 诱导性细胞外囊泡在制备治疗肿瘤药物中的应用
EP4150054A4 (en) 2020-05-11 2025-08-27 Strm Bio Incorporated COMPOSITIONS AND METHODS RELATING TO MEGAKARYOCYTE-DERIVED EXTRACELLULAR VESICLES
KR102601831B1 (ko) * 2020-09-23 2023-11-14 대한민국 고형암 증식 억제 효과를 갖는 개과동물의 엑소좀
EP4534649A1 (en) * 2023-10-03 2025-04-09 Unicyte AG A method of qualifying as pharmaceutically active a batch of undifferentiated adult stem cells having the potential to differentiate along the hepatic lineage

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009087361A1 (en) * 2008-01-04 2009-07-16 Lydac Neuroscience Limited Microvesicles
WO2009105044A1 (en) * 2008-02-22 2009-08-27 Agency For Science, Technology And Research (A*Star) Mesenchymal stem cell particles

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6088613A (en) * 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
EP0964676A1 (en) * 1997-01-30 1999-12-22 Quadrant Healthcare (UK) Limited Microparticles and their use in cancer treatment
ES2244169T3 (es) * 1998-02-09 2005-12-01 Bracco International B.V. Suministro direccionado de medios biologicamente activos.
US20020177551A1 (en) * 2000-05-31 2002-11-28 Terman David S. Compositions and methods for treatment of neoplastic disease
US7128903B2 (en) * 2001-10-03 2006-10-31 Innovative Pharmaceutical Concepts (Ipc) Inc. Pharmaceutical preparations useful for treating tumors and lesions of the skin and the mucous membranes and methods and kits using same
WO2005121369A2 (en) * 2004-06-02 2005-12-22 Sourcepharm, Inc. Rna-containing microvesicles and methods therefor
US8148335B2 (en) * 2004-06-23 2012-04-03 Children's Hospital & Research Center Oakland De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
GB0501129D0 (en) * 2005-01-19 2005-02-23 Ribostem Ltd Method of treatment by administration of RNA
WO2006126219A1 (en) 2005-05-26 2006-11-30 Fresenius Medical Care Deutschland G.M.B.H. Liver progenitor cells
TWI479559B (zh) 2007-06-28 2015-04-01 Quantum Global Tech Llc 以選擇性噴灑蝕刻來清潔腔室部件的方法和設備
BRPI0816852A2 (pt) * 2007-09-14 2017-06-06 Univ Ohio State Res Found método de diagnosticar ou prognosticar doença ou desordem em sujeito, biomarcador, método para determinar e/ou prever se sujeito tem diferenciação da desordem, biomarcador para desordem pulmonar, método para diagnosticar se sujeito tem, ou está em risco de desenvolver doença ou desordem, método de inibir a proliferação de doença ou desordem e método para identificar agente terapêutico do câncer.
CN101896188B (zh) 2007-10-15 2013-01-02 弗雷森纽斯医疗护理德国有限责任公司 微泡(mv)用于制备对内皮细胞移植具有佐剂活性、特别是对通过胰岛移植进行的糖尿病治疗具有佐剂活性的药物的用途，和相关方法
PL2211875T3 (pl) * 2007-10-29 2013-11-29 Fresenius Medical Care Deutschland Gmbh Zastosowanie mikropęcherzyków (MV) pochodzących z komórek macierzystych do wytwarzania leku do regeneracji śródbłonkowej/nabłonkowej uszkodzonych lub poddanych urazowi tkanek lub narządów i związane z nimi sposoby in vitro i in vivo
EP2186883A1 (en) 2008-11-04 2010-05-19 Fresenius Medical Care An isolated multipotent mesenchymal stem cell from human adult glomeruli (hGL-MSC), a method of preparing thereof and uses thereof in the regenerative medicine of the kidney
EP2363136A1 (en) * 2010-03-02 2011-09-07 Fresenius Medical Care Deutschland GmbH Microvesicles (MVs) derived from adult stem cells for use in the therapeutic treatment of a tumor disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009087361A1 (en) * 2008-01-04 2009-07-16 Lydac Neuroscience Limited Microvesicles
WO2009105044A1 (en) * 2008-02-22 2009-08-27 Agency For Science, Technology And Research (A*Star) Mesenchymal stem cell particles

Also Published As

Publication number Publication date
US20170348356A1 (en) 2017-12-07
HUE026292T2 (en) 2016-05-30
JP5841952B2 (ja) 2016-01-13
US10105395B2 (en) 2018-10-23
US20230248774A1 (en) 2023-08-10
WO2011107437A1 (en) 2011-09-09
PL2542250T3 (pl) 2016-04-29
US20120321723A1 (en) 2012-12-20
EP2542250A1 (en) 2013-01-09
EP2363136A1 (en) 2011-09-07
EP2542250B1 (en) 2015-08-26
ES2554492T3 (es) 2015-12-21
CN102781454A (zh) 2012-11-14
US9717760B2 (en) 2017-08-01
JP2013520971A (ja) 2013-06-10
DK2542250T3 (en) 2015-12-07
PT2542250E (pt) 2015-12-09
US20190060369A1 (en) 2019-02-28

Similar Documents

Publication Publication Date Title
CN102781454B (zh) 用于治疗性治疗肿瘤疾病的来源于成体干细胞的微泡（mv）
JP5261494B2 (ja) 損傷しまたは傷害を受けた組織または臓器の内皮／上皮再生用医薬の製造のための、幹細胞由来微小胞（ｍｖ）の使用ならびにインビトロおよびインビボでの関連した方法
Li et al. Autologous bone marrow-derived mesenchymal stem cell transplantation promotes liver regeneration after portal vein embolization in cirrhotic rats
RU2535966C2 (ru) Клеточная терапия ишемической ткани
Pisati et al. Effect of human skin-derived stem cells on vessel architecture, tumor growth, and tumor invasion in brain tumor animal models
Gong et al. Human umbilical cord blood derived mesenchymal stem cells improve cardiac function in cTnTR141W transgenic mouse of dilated cardiomyopathy
Taghavi et al. Autologous c‐Kit+ mesenchymal stem cell injections provide superior therapeutic benefit as compared to c‐Kit+ cardiac‐derived stem cells in a feline model of isoproterenol‐induced cardiomyopathy
CN101272798A (zh) 基因修饰以表达自杀基因的骨髓间充质干细胞用于治疗癌症的用途
US11406685B2 (en) Methods and compositions for stimulation of cell proliferation and provision of biologically active mixtures of FGF2 isoforms
Wood et al. Distinct contribution of human cord blood‐derived endothelial colony forming cells to liver and gut in a fetal sheep model
JP5339533B2 (ja) 血管内皮前駆細胞の移植による抗がん療法
KR101796826B1 (ko) Oct4 및 Sox2를 과발현하는 중간엽줄기세포 및 그 용도
de Oliveira et al. Priming mesenchymal stem cells with endothelial growth medium boosts stem cell therapy for systemic arterial hypertension
KR20190039700A (ko) 다능성 간세포에 의한 허혈재관류 폐장애의 경감 및 치료
KR102360990B1 (ko) 혈관장해의 예방 또는 치료제
Lai et al. Comparison of the biological and functional characteristics of mesenchymal stem cells from intrahepatic and identical bone marrow
JP5686841B2 (ja) 損傷しまたは傷害を受けた組織または臓器の内皮／上皮再生用医薬の製造のための、幹細胞由来微小胞（ｍｖ）の使用ならびにインビトロおよびインビボでの関連した方法
JP2009508511A (ja) ヒト平滑筋細胞の獲得方法およびヒト平滑筋細胞の適用
JP2009508511A5 (enExample)
Sastourne-Arrey et al. Adipose tissue is a source of fibro-adipogenic progenitors for regenerating skeletal muscles
WO2011154505A2 (en) Complex product comprising a cellular carrier and a cytoxic chemotherapeutic drug
US20060127367A1 (en) Compositions containing macrophages and uses thereof
Fazel Cardiac repair and not regeneration after myocardial infarction: the role and therapeutic utility of the c-kitSCF pathway.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant